Market News & Trends
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
Denali Therapeutics Inc. recently announced the US FDA has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot…
Ecolab Life Sciences & Repligen Announce Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
St. Paul, MN, US and Waltham, MA, US – June 3, 2024 – Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life…
Longeveron Announces Contract Development & Manufacturing Business & First Contract
Longeveron Inc. recently announced the launch of its contract development and manufacturing business at the company’s 15,000-sq-ft state-of-the-art Good Manufacturing Practice (GMP) facility. This facility contains….
Aeterna Zentaris & Ceapro Complete Merger Transaction
Aeterna Zentaris Inc. and Ceapro Inc. recently announce the successful completion and closing of their all-stock merger of equals transaction (the Transaction), which was previously announced by….
uniQure Receives FDA Regenerative Medicine Advanced Therapy Designation for Investigational Gene Therapy in Huntington’s Disease
uniQure N.V. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy AMT-130 for the treatment of…
PhoreMost Achieves Second Milestone in Target Discovery Alliance With Boehringer Ingelheim
PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel…
Anocca AB & Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology
Anocca AB and Shinobi Therapeutics recently announced a strategic partnership to use Shinobi’s proprietary immune evasive iPS-T cell platform with novel candidate TCRs, discovered and…
Nxera Pharma & PrecisionLife Expand Strategic R&D Partnership Into New Therapeutic Area
Nxera Pharma Co. Ltd and PrecisionLife recently announced the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug…
Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma
Elevar Therapeutics, Inc. recently announced the landmark overall survival (OS) analysis of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC) will…
Patient Dosing Commenced in Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients With Obstructive Sleep Apnea
Incannex Healthcare Inc. recently announce patient dosing has commenced in the company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients…
Sanofi Completes Acquisition of Inhibrx, Inc.
Sanofi recently announced the completion of its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, underscoring the company’s…
Nxera Pharma to Receive $4.6 Million in Milestone Payments Rrom Centessa Pharmaceuticals
Nxera Pharma recently announced it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used…
Jeito Capital Announces Acquisition by Merck & Co. of its Portfolio Company EyeBio for a Potential Value of $3 Billion
This acquisition reflects the significant clinical progress achieved with Restoret, EyeBio’s novel late-phase candidate for diabetic macular edema, as well as….
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
Skinvisible Pharmaceuticals, Inc. recently announced a major advancement in the battle against obesity. The company has achieved a significant milestone by officially filing a provisional patent application covering formulations that….
Vyluma Announces Marketing Authorization Application Validation for the European Union
Vyluma, Inc. recently announced the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for its lead compound, NVK002. The application is confirmed…
BioNTech & CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine…
Evonik Drives Sustainable Biosurfactant Revolution With Inauguration of New Facility in Slovakia
First facility worldwide to manufacture industrial-scale rhamnolipid biosurfactants; huge potential in personal care, cleaning, coatings, animal nutrition, agriculture, and many other applications….
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation From the EMA for the Treatment of Chronic Hepatitis D
Bluejay Therapeutics recently announced the European Medicines Agency (EMA) has issued a positive opinion on the company’s application for orphan designation for BJT-778 for the…
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
ProBioGen recently announced a pivotal collaboration with ModeX Therapeutics an OPKO Health Company dedicated to combating cancer and infectious diseases with cutting-edge….
Kindeva Global Health Security Donates ATNAA to Ukraine Through the European Commission’s rescEU & Governmental Strategic Reserves Agency (RARS)
Kindeva Drug Delivery recently announced it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the…